National Advertising Division Recommends Bayer Modify or Discontinue Certain One A Day Men’s Pre-Conception Health Complete Multivitamin Claims
New York, NY – March 31, 2026 – Following a challenge brought by OLLY PBC, BBB National Programs’ National Advertising Division recommended that Bayer HealthCare LLC discontinue or modify certain claims for its One A Day® Men’s Pre-Conception Health Complete Multivitamin, a product marketed for men who are trying to conceive.
OLLY and Bayer are competitors in the dietary supplement market. OLLY challenged Bayer’s claims that Bayer’s One A Day Men’s Pre-Conception Health Complete Multivitamin supports healthy sperm and contains “powerful” antioxidants, including lycopene, as well as Bayer’s use of the term “complete multivitamin.”
The National Advertising Division (NAD) found that certain claims, including that men should take the product for at least three months before conception and that the product is specially designed to provide nutritional support while trying to conceive, reasonably convey the message that the product improves men’s chances of conception.
NAD also found that, in the fertility-focused context, certain claims that the product supports healthy sperm reasonably convey the message that the product improves sperm health and viability.
NAD found that the ingredient testing in the record did not support the challenged claims and recommended that Bayer discontinue or modify these claims to avoid conveying the unsupported message that the Men’s Pre-Conception Health Complete Multivitamin will improve chances of conception or that it improves sperm health and viability.
NAD also reviewed Bayer’s claim that the product contains “powerful antioxidants including Vitamin C, Vitamin E, selenium, zinc, and Lycopene which support healthy sperm.” NAD found that this claim conveys the message that the identified nutrients are responsible for delivering the claimed sperm-related benefits and that lycopene exhibits powerful antioxidant activity in the product.
Because the evidence did not support those messages, NAD recommended that Bayer discontinue or modify the claim.
With respect to Bayer’s use of the term “complete multivitamin,” NAD concluded that, in the absence of extrinsic evidence demonstrating consumer confusion caused by the product name, it would not recommend a change to the product name.
In its advertiser statement, Bayer stated that it will comply with NAD’s recommendations.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. This press release shall not be used for advertising or promotional purposes.
OLLY and Bayer are competitors in the dietary supplement market. OLLY challenged Bayer’s claims that Bayer’s One A Day Men’s Pre-Conception Health Complete Multivitamin supports healthy sperm and contains “powerful” antioxidants, including lycopene, as well as Bayer’s use of the term “complete multivitamin.”
The National Advertising Division (NAD) found that certain claims, including that men should take the product for at least three months before conception and that the product is specially designed to provide nutritional support while trying to conceive, reasonably convey the message that the product improves men’s chances of conception.
NAD also found that, in the fertility-focused context, certain claims that the product supports healthy sperm reasonably convey the message that the product improves sperm health and viability.
NAD found that the ingredient testing in the record did not support the challenged claims and recommended that Bayer discontinue or modify these claims to avoid conveying the unsupported message that the Men’s Pre-Conception Health Complete Multivitamin will improve chances of conception or that it improves sperm health and viability.
NAD also reviewed Bayer’s claim that the product contains “powerful antioxidants including Vitamin C, Vitamin E, selenium, zinc, and Lycopene which support healthy sperm.” NAD found that this claim conveys the message that the identified nutrients are responsible for delivering the claimed sperm-related benefits and that lycopene exhibits powerful antioxidant activity in the product.
Because the evidence did not support those messages, NAD recommended that Bayer discontinue or modify the claim.
With respect to Bayer’s use of the term “complete multivitamin,” NAD concluded that, in the absence of extrinsic evidence demonstrating consumer confusion caused by the product name, it would not recommend a change to the product name.
In its advertiser statement, Bayer stated that it will comply with NAD’s recommendations.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. This press release shall not be used for advertising or promotional purposes.